MELK inhibitors (Janssen Pharmaceutica NV/University Hospital Leuven/Astex Therapeutics)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameMELK inhibitors (Janssen Pharmaceutica NV/University Hospital Leuven/Astex Therapeutics)
Drug Alias NameMELK-T1JNJ-47117096MELK-T2JNJ-45261957
ClassificationSmall molecules
Mechanisms of ActionMaternal embryonic leucine zipper kinase inhibitorsAnticancer protein kinase inhibitorsNeuroprotectants +[5] 
TargetsGamma-secretaseMaternal embryonic leucine zipper kinase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesJanssen Pharmaceutica NV
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJanssen Pharmaceutica NVAstex Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A